Response to: Correspondence on 'H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2+ patients with diffuse midline glioma' by Chheda et al
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2023-03-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/11/3/e006784.full |
| _version_ | 1797868342161178624 |
|---|---|
| author | Thomas Blankenstein Lena Immisch George Papafotiou Oliver Popp Philipp Mertins Gerald Willimsky |
| author_facet | Thomas Blankenstein Lena Immisch George Papafotiou Oliver Popp Philipp Mertins Gerald Willimsky |
| author_sort | Thomas Blankenstein |
| collection | DOAJ |
| first_indexed | 2024-04-09T23:54:22Z |
| format | Article |
| id | doaj.art-2c94b19ad4ba480790836277e4e500f6 |
| institution | Directory Open Access Journal |
| issn | 2051-1426 |
| language | English |
| last_indexed | 2024-04-09T23:54:22Z |
| publishDate | 2023-03-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Journal for ImmunoTherapy of Cancer |
| spelling | doaj.art-2c94b19ad4ba480790836277e4e500f62023-03-17T04:30:06ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262023-03-0111310.1136/jitc-2023-006784Response to: Correspondence on 'H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2+ patients with diffuse midline glioma' by Chheda et alThomas Blankenstein0Lena Immisch1George Papafotiou2Oliver Popp3Philipp Mertins4Gerald Willimsky5Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, GermanyInstitute of Immunology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, GermanyInstitute of Immunology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, GermanyMax Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, GermanyMax Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, GermanyInstitute of Immunology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germanyhttps://jitc.bmj.com/content/11/3/e006784.full |
| spellingShingle | Thomas Blankenstein Lena Immisch George Papafotiou Oliver Popp Philipp Mertins Gerald Willimsky Response to: Correspondence on 'H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2+ patients with diffuse midline glioma' by Chheda et al Journal for ImmunoTherapy of Cancer |
| title | Response to: Correspondence on 'H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2+ patients with diffuse midline glioma' by Chheda et al |
| title_full | Response to: Correspondence on 'H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2+ patients with diffuse midline glioma' by Chheda et al |
| title_fullStr | Response to: Correspondence on 'H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2+ patients with diffuse midline glioma' by Chheda et al |
| title_full_unstemmed | Response to: Correspondence on 'H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2+ patients with diffuse midline glioma' by Chheda et al |
| title_short | Response to: Correspondence on 'H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2+ patients with diffuse midline glioma' by Chheda et al |
| title_sort | response to correspondence on h3 3k27m mutation is not a suitable target for immunotherapy in hla a2 patients with diffuse midline glioma by chheda et al |
| url | https://jitc.bmj.com/content/11/3/e006784.full |
| work_keys_str_mv | AT thomasblankenstein responsetocorrespondenceonh33k27mmutationisnotasuitabletargetforimmunotherapyinhlaa2patientswithdiffusemidlinegliomabychhedaetal AT lenaimmisch responsetocorrespondenceonh33k27mmutationisnotasuitabletargetforimmunotherapyinhlaa2patientswithdiffusemidlinegliomabychhedaetal AT georgepapafotiou responsetocorrespondenceonh33k27mmutationisnotasuitabletargetforimmunotherapyinhlaa2patientswithdiffusemidlinegliomabychhedaetal AT oliverpopp responsetocorrespondenceonh33k27mmutationisnotasuitabletargetforimmunotherapyinhlaa2patientswithdiffusemidlinegliomabychhedaetal AT philippmertins responsetocorrespondenceonh33k27mmutationisnotasuitabletargetforimmunotherapyinhlaa2patientswithdiffusemidlinegliomabychhedaetal AT geraldwillimsky responsetocorrespondenceonh33k27mmutationisnotasuitabletargetforimmunotherapyinhlaa2patientswithdiffusemidlinegliomabychhedaetal |